Citation(s)
- Foster RH, Faulds D
Abacavir. Drugs. 1998 May;55(5):729-36; discussion 737-8. Review.
- Galadari I, Rigel E, Lebwohl M
The cost of psoriasis treatment. J Eur Acad Dermatol Venereol. 2001 Jul;15(4):290-1.
- Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct;23(10):1603-14.
- Imamichi T
Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des. 2004;10(32):4039-53. Review.
- Sonkoly E, Bata-Csorgo Z, Pivarcsi A, Polyanka H, Kenderessy-Szabo A, Molnar G, Szentpali K, Bari L, Megyeri K, Mandi Y, Dobozy A, Kemeny L, Szell M
Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS. J Biol Chem. 2005 Jun 24;280(25):24159-67. Epub 2005 Apr 26.
- Tzu J, Kerdel F
From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther. 2008 Mar-Apr;21(2):131-41. doi: 10.1111/j.1529-8019.2008.00180.x. Review.
A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol™) and Oral Abacavir Sulfate (Ziagen®) in Healthy Volunteers
Details for clinical trial NCT02101216
